Showing results (151-160 of 2,467) with videos related to

Sort By:
Pageof 247
Gynecologic Oncology|May 5, 2019
Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancerKumaravel Mohankumar, Xi Li, Subhashree Sridharan, et al.
Molecular Cancer Therapeutics|May 14, 2009
The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expressionXinyi Liu, Maen Abdelrahim, Ala Abudayyeh, et al.
Endocrinology|July 19, 2008
In vivo profiling of estrogen receptor/specificity protein-dependent transactivationFei Wu, Rui Xu, Kyounghyun Kim, et al.
BMC Cancer|July 12, 2014
The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasisUn-Ho Jin, Syng-Ook Lee, Catherine Pfent, et al.
Toxicology Letters|March 29, 2006
Effects of benzo-a-pyrene on oxytocin-induced Ca2+ oscillations in myometrial cellsRola Barhoumi, Igbal Awooda, Youssef Mouneimne, et al.
Endocrine-Related Cancer|August 1, 2015
Nuclear receptor 4A1 as a drug target for breast cancer chemotherapyErik Hedrick, Syng-Ook Lee, Ravi Doddapaneni, et al.
Oncotarget|April 28, 2015
The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migrationYating Cheng, Indira Jutooru, Gayathri Chadalapaka, et al.
American Journal of Cancer Research|August 15, 2022
Short chain fatty acids exhibit selective estrogen receptor downregulator (SERD) activity in breast cancerAbigail Schoeller, Keshav Karki, Arul Jayaraman, et al.
Oncotarget|March 12, 2016
Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cellsErik Hedrick, Yating Cheng, Un-Ho Jin, et al.
Current Opinion in Toxicology|August 28, 2019
Aryl Hydrocarbon Receptor (AhR) Ligands as Selective AhR Modulators: Genomic StudiesStephen Safe, Huajun Han, Jennifer Goldsby, et al.
Pageof 247